HCM
DMII

Highbridge Capital Management’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Highbridge Capital Management’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6M Buy
2,241,215
+2,016,211
+896% +$20.2M 0.55% 36
2026
Q1 		$2.25M Buy
+225,004
New +$2.24M 0.07% 123

Other funds holding DMII

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Highbridge Capital Management's DMII Position: Q2 2026 in Review

Highbridge Capital Management increased its Drugs Made In America Acquisition II Corp (DMII) stake by 896% in Q2 2026, buying an estimated $20.2M and bringing the position to 2,241,215 shares worth $22.6M. The position accounts for 0.55% of the portfolio, ranked #36.

Highbridge Capital Management first reported a position in DMII in Q1 2026 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • Highbridge Capital Management held 2,241,215 shares of Drugs Made In America Acquisition II Corp worth $22.6M as of Q2 2026.
  • Highbridge Capital Management bought 2,016,211 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $20.2M.
  • Drugs Made In America Acquisition II Corp made up 0.55% of Highbridge Capital Management's portfolio in Q2 2026, its #36 holding.
  • Highbridge Capital Management first reported a position in Drugs Made In America Acquisition II Corp in Q1 2026 and has held it in 2 quarters since.
  • 69 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Highbridge Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.